View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 29, 2020updated 23 Nov 2020 6:34pm

XtalPi raises $318m to support AI-based drug discovery

Artificial intelligence (AI)-based drug discovery company XtalPi has raised $318.8m in a Series C funding round co-led by SoftBank Vision Fund 2, PICC Capital and Morningside.

Artificial intelligence (AI)-based drug discovery company XtalPi has raised $318.8m in a Series C funding round co-led by SoftBank Vision Fund 2, PICC Capital and Morningside.

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

Several global investment companies in banking and technology took part in the financing round, along with existing investors Tencent, Sequoia China, China Life and SIG.

The company plans to use the funds to scale up its AI and cloud computing-powered platform to enable discovery of drug candidates with individualised pharmaceutical profiles.

XtalPi platform integrates physics-based and data-driven models to address drug properties necessary for advancement into clinical studies.

The company will use its virtual R&D platform predictions and real-world data to create a digital-twin drug R&D system to help find drug candidates with fewer experiments and in less time.

XtalPi also plans to develop the capabilities of its Intelligent Digital Drug Discovery and Development (ID4) platform using algorithms, data and computing power. The aim is to address efficiency challenges during research.

XtalPi chairman and co-founder Dr Shuhao Wen said: “More specifically, XtalPi’s AI-powered platform can improve the industry’s research efficiency and success rate in order to lower costs for discovering and developing new drugs.

“We look forward to applying our platform to help clients bring more first-in-class and breakthrough drugs to the market and address significant unmet medical needs to benefit patients on a global scale.”

XtalPi raised $46m in a Series B-1 extension financing round in 2018 for market growth and to expand its technology’s use into new pharmaceutical research areas.

In May 2018, XtalPi entered an alliance with Pfizer to develop a physics and AI-powered molecular modelling platform for drug discovery

Related Companies

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU